Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Capital Employed: 2020-2025

Historic Return on Capital Employed for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to -0.32%.

  • Kymera Therapeutics' Return on Capital Employed fell 9.00% to -0.32% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.32%, marking a year-over-year decrease of 9.00%. This contributed to the annual value of -0.37% for FY2024, which is 4.00% down from last year.
  • Per Kymera Therapeutics' latest filing, its Return on Capital Employed stood at -0.32% for Q3 2025, which was up 4.45% from -0.33% recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Return on Capital Employed ranged from a high of -0.13% in Q1 2021 and a low of -0.37% during Q3 2023.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.31% (2025), whereas its average is -0.30%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first dropped by 14bps in 2022, then rose by 14bps in 2024.
  • Kymera Therapeutics' Return on Capital Employed (Quarterly) stood at -0.19% in 2021, then decreased by 10bps to -0.29% in 2022, then dropped by 5bps to -0.35% in 2023, then climbed by 7bps to -0.28% in 2024, then dropped by 9bps to -0.32% in 2025.
  • Its last three reported values are -0.32% in Q3 2025, -0.33% for Q2 2025, and -0.31% during Q1 2025.